BACKGROUND: We evaluate the current prevalence of serologic markers for hepatitis B virus (HBV) and hepatitis C virus (HCV) in blood donors and estimated HCV incidence and residual transfusion-transmitted risk at three large Brazilian blood centers. STUDY DESIGN AND METHODS: Data on whole blood and platelet donations were collected from January through December 2007, analyzed by center; donor type; age; sex; donation status; and serologic results for hepatitis B surface antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBc), and anti-HCV. HBV and HCV prevalence rates were calculated for all first-time donations. HCV incidence was derived including interdonation intervals that preceded first repeat donations given during the study, and HCV residual risk was estimated for transfusions derived from repeat donors. RESULTS: There were 307,354 donations in 2007. Overall prevalence of concordant HBsAg and anti-HBc reactivity was 289 per 100,000 donations and of anti-HCV confirmed reactivity 191 per 100,000 donations. There were significant associations between older age and hepatitis markers, especially for HCV. HCV incidence was 3.11 (95% confidence interval, 0.77-7.03) per 100,000 person-years, and residual risk of HCV window-phase infections was estimated at 5.0 per million units transfused. CONCLUSION: Improvement in donor selection, socioeconomic conditions, and preventive measures, implemented over time, may have helped to decrease prevalence of HBV and HCV, relative to previous reports. Incidence and residual risk of HCV are also diminishing. Ongoing monitoring of HBV and HCV markers among Brazilian blood donors should help guide improved recruitment procedures, donor selection, laboratory screening, and counseling strategies.
BACKGROUND: We evaluate the current prevalence of serologic markers for hepatitis B virus (HBV) and hepatitis C virus (HCV) in blood donors and estimated HCV incidence and residual transfusion-transmitted risk at three large Brazilian blood centers. STUDY DESIGN AND METHODS: Data on whole blood and platelet donations were collected from January through December 2007, analyzed by center; donor type; age; sex; donation status; and serologic results for hepatitis B surface antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBc), and anti-HCV. HBV and HCV prevalence rates were calculated for all first-time donations. HCV incidence was derived including interdonation intervals that preceded first repeat donations given during the study, and HCV residual risk was estimated for transfusions derived from repeat donors. RESULTS: There were 307,354 donations in 2007. Overall prevalence of concordant HBsAg and anti-HBc reactivity was 289 per 100,000 donations and of anti-HCV confirmed reactivity 191 per 100,000 donations. There were significant associations between older age and hepatitis markers, especially for HCV. HCV incidence was 3.11 (95% confidence interval, 0.77-7.03) per 100,000 person-years, and residual risk of HCV window-phase infections was estimated at 5.0 per million units transfused. CONCLUSION: Improvement in donor selection, socioeconomic conditions, and preventive measures, implemented over time, may have helped to decrease prevalence of HBV and HCV, relative to previous reports. Incidence and residual risk of HCV are also diminishing. Ongoing monitoring of HBV and HCV markers among Brazilian blood donors should help guide improved recruitment procedures, donor selection, laboratory screening, and counseling strategies.
Authors: Susan L Stramer; Shimian Zou; Edward P Notari; Gregory A Foster; David E Krysztof; Fatemeh Musavi; Roger Y Dodd Journal: Transfusion Date: 2011-08-02 Impact factor: 3.157
Authors: Ester C Sabino; Thelma T Gonçalez; Anna Bárbara Carneiro-Proietti; Moussa Sarr; João Eduardo Ferreira; Divaldo A Sampaio; Nanci A Salles; David J Wright; Brian Custer; Michael Busch Journal: Transfusion Date: 2011-10-07 Impact factor: 3.157
Authors: Claudia C Barreto; Ester C Sabino; Thelma T Gonçalez; Megan E Laycock; Brandee L Pappalardo; Nanci A Salles; David J Wright; Dalton F Chamone; Michael P Busch Journal: Transfusion Date: 2005-11 Impact factor: 3.157
Authors: Aline G Vigani; Maria H Pavan; Raquel Tozzo; Eduardo S L Gonçales; Adriana Feltrin; Viviane C Fais; Maria S K Lazarini; Neiva S L Gonçales; Fernando L Gonçales Journal: BMC Infect Dis Date: 2008-12-04 Impact factor: 3.090
Authors: Paula F Blatyta; Shannon Kelly; Ester Sabino; Liliana Preiss; Franciane Mendes; Anna B Carneiro-Proietti; Daniela de Oliveira Werneck Rodrigues; Rosimere Mota; Paula Loureiro; Claudia Maximo; Miriam Park; Alfredo Mendrone-Jr; Thelma T Gonçalez; Cesar de Almeida Neto; Brian Custer Journal: Transfusion Date: 2019-12-05 Impact factor: 3.157
Authors: Donald J Brambilla; Michael P Busch; Roger Y Dodd; Simone A Glynn; Steven H Kleinman Journal: Transfusion Date: 2016-12-01 Impact factor: 3.157
Authors: Paula Loureiro; Cesar de Almeida-Neto; Anna Bárbara Carneiro Proietti; Ligia Capuani; Thelma Terezinha Gonçalez; Claudia Di Lorenzo de Oliveira; Silvana Carneiro Leão; Maria Inês Lopes; Divaldo Sampaio; Giuseppina Maria Patavino; João Eduardo Ferreira; Paula Fraiman Blatyta; Maria Esther Duarte Lopes; Alfredo Mendrone-Junior; Nanci Alves Salles; Melissa King; Edward Murphy; Michael Busch; Brian Custer; Ester Cerdeira Sabino Journal: Rev Bras Hematol Hemoter Date: 2014-03
Authors: Angelita Silva de Miranda Corrêa; Letícia Martins Lamarão; Priscilla Cristina Moura Vieira; Renata Bezerra Hermes de Castro; Núbia Caroline Costa de Almeida; Jairo Augusto Américo de Castro; Maria Salete Maciel de Lima; Mauricio Koury Palmeira; Ana Luiza Langanke Pedroso Meireles; Rommel Rodríguez Burbano Journal: PLoS One Date: 2018-12-19 Impact factor: 3.240
Authors: Anna S Nishiya; Cesar de Almeida-Neto; Suzete C Ferreira; Cecília S Alencar; Claudia Di-Lorenzo-Oliveira; José E Levi; Nanci A Salles; Alfredo Mendrone; Ester C Sabino Journal: PLoS One Date: 2014-01-21 Impact factor: 3.240
Authors: Francisco Augusto Porto Ferreira; Cesar de Almeida-Neto; Maria Cristina Dias Teixeira; Edna Strauss Journal: Rev Bras Hematol Hemoter Date: 2015-09-13